Pulmonary Surfactant Market Increasing preference of animal derived surfactant for the treatment of respiratory distress syndrome is driving the market growth | Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc

In order to reduce surface tension and maintain lung volumes during end expiration, pulmonary surfactant, a complex mixture of phospholipids and proteins, generates a special interface at the alveolar cell surface that separates alveolar gas and liquids. Following birth, breathing requires the surface tension at the air-liquid interface to be reduced. Infantile respiratory distress syndrome, or respiratory failure in premature newborns, is brought on by pulmonary surfactant deficiency (IRDS). Unique and tightly controlled processes that control the synthesis, secretion, reutilization, and catabolism of pulmonary surfactant maintain the substance’s adequate levels. Adult respiratory distress syndrome (ARDS), a substantial cause of morbidity and mortality following illness, shock, or trauma, is characterised by the loss or inactivation of lung surfactant later in life. In newborn newborns, young children, and adults, mutations in the genes SFTPA, SFTPB, SFTPC, ABCA3, TITF1, and CSF2RA that control surfactant homeostasis can result in acute or chronic lung illness. Pulmonary alveolar proteinosis is caused by abnormalities in GM-CSF signalling, which prevent alveolar macrophages from metabolising surfactant lipids and proteins (PAP).

The market for pulmonary surfactants was estimated at US$ 578.7 million in 2022 and is anticipated to grow at a CAGR of 4.50% over the next five years (2022 – 2030).

Click Here for Sample Copy (Use corporate email ID Get Higher Priority) @ https://www.coherentmarketinsights.com/insight/request-sample/5324

Market Drivers

The demand for animal-derived surfactants to treat respiratory distress syndrome is expected to increase over the course of the forecast period.

The demand for animal-derived surfactants to treat respiratory distress syndrome is expected to increase over the course of the forecast period. For instance, Poractant alfa (Curosurf), according to an article published in the open access, peer reviewed Journal Archives of Clinical and Medical Case Reports in May 2021, significantly decreased the rates of pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing the lung to collapse) in preterm infants with respiratory distress syndrome. Compared to infants who were not VLBW (very low birth weight), this decline was more pronounced in VLBW infants.

Additionally, on April 11, 2022, an article from the National Center for Biotechnology Information, a division of the National Institutes of Health, reported that the use of animal-derived pulmonary surfactant in conjunction with the corticosteroid or steroid budesonide can successfully reduce the duration of invasive mechanical ventilation, the need for BPD, as well as the length of hospital stays (bronchopulmonary dysplasia). It does not, however, raise the chance of fatal complications or other connected outcomes. This strategy can be used in clinical settings.

In the global market for pulmonary surfactants, North America holds the largest market share due to the rising prevalence of respiratory illnesses.

Over the projected period, rising rates of respiratory illnesses in the U.S. are anticipated to fuel market expansion.

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/5324

For instance, the RSV (Respiratory Syncytial Virus) causes an average of 58,000 hospitalizations with 100–500 deaths among children under the age of five and 177,000 hospitalizations with 14,000 deaths among adults 65 and older each year in the United States, according to the Centers for Disease Control and Prevention, a national public health organisation of the country. RSV infection puts infants, young children, and older people with ongoing medical conditions at risk for developing serious illness.

Impact

Over the projection period, market growth is anticipated to be fueled by an increase in research and development among the major players in the pulmonary surfactant industry due to the COVID-19 pandemic. For instance, results from the Phase 2 study of lucinactant (KL4 surfactant) for patients with severe COVID-19 associated acute respiratory distress syndrome (ARDS) and lung injury were released on March 22, 2022 by Windtree Therapeutics, Inc., a biotechnology company with multiple late-stage interventions for acute cardiovascular and pulmonary disorders. The study’s main finding was that the angiotensin-converting enzyme 2 (ACE2) receptor is used by the SARS-CoV-2 virus to enter host cells and cause COVID-19. The objective of the Phase 2 experiment was to evaluate the feasibility, safety, and tolerability of giving these critically ill patients reconstituted lyophilized lucinactant.

Key Developments

For instance, J.K. Lon Government Children Hospital (India) introduced the less invasive surfactant administration treatment (LISA) for neonatal respiratory distress syndrome in May 2020. The LISA technique is very helpful because the surfactant is administered via thin feeding tube and removed right away after the procedure is finished, minimising the side effects caused by prolonged exposure to ventilators.

In February 2020, a clinical-stage biopharmaceutical and medical device firm named Windtree Therapeutics began a research on the effectiveness and safety of inhaling Lucinactant in preterm infants between 26 and 32 weeks of age who had neonatal respiratory distress. The study involved preterm newborns between 26 and 32 completed weeks PMA and was international, multicenter, double-blind (masked), parallel group, randomised, controlled (Post-menstrual age).

The clinical trial of a novel procedure called IN-REC-SUR-E, IN-SUR-E alone in spontaneously breathing preterm infants needing nasal continuous positive airway pressure (nCPAP) as initial respiratory support and reaching pre-defined CPAP failure criteria, in preterm neonates with respiratory distress syndrome was completed in September 2018 at the Catholic University of Sacred Heart. The Proactant Alfa medication, a newborn continuous positive air pressure nasal cap, and a high frequency oscillating ventilator are all used in the treatment.

Market Restraints

The market for pulmonary surfactants is constrained by the rising number of negative effects linked to pulmonary surfactant medications. The medications used to treat respiratory diseases have a number of unwanted side effects. For example, a report released on March 3, 2022 by RxList Inc, a company that provides comprehensive and up-to-date pharmaceutical information on brand-name and generic drugs, states that common side effects of Surfaxin, a liquid medication used to treat infant respiratory distress syndrome, are connected to its administration down a premature infant’s breathing tube (endotracheal tube), and include endotracheal tube reflux, skin pallor, endotracheal tube obstruction, and a fever.

Key Players

Reddot Biotech, Boehinger Ingelheim, Nanjing Norris Pharm Technology, AbbVie Inc., Biomatik, Chiesi Farmaceutici, Tekzima (Noargen), ONY Biotech Inc., Windtree Therapeutics, Inc., Lyomark Pharma, Aviva Systems Biology Corporation, and Abbott, are important market participants in the pulmonary surfactant market.

Avail Discount on various license types on Immediate Purchase @ https://www.coherentmarketinsights.com/insight/buy-now/5324